Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project
Objective: To characterize patients with early versus later levodopa exposure, defining “early” as within 2 years of Parkinson’s disease (PD) diagnosis, and to determine whether…Predictors of survival in Progressive Supranuclear Palsy in a Tunisian cohort
Objective: To investigate survival and its determinants in a Tunisian cohort of Progressive Supranuclear Palsy (PSP). Background: PSP is a neurodegenerative tauopathy characterized by faster…How Covid-19 would affect parkinsonism patients’ mortality
Objective: To investigate the prevalence and mortality of Covid-19 among parkinsonism patients in addition to worsening of motor symptoms of these patients. Background: Parkinsonism can…Determination of 5-HT3 receptor levels with [3H]-GR 65630 binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of serotonin type 3 (5-HT3) receptors in brain areas implicated in L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat…The prevalence of sarcopenia in Parkinson’s disease and related disorders
Objective: To systematically review the prevalence of sarcopenia in Parkinson’s disease (PD) and atypical parkinsonian syndromes (aPS), how prevalence differs with PD stage and between…The Use Of Bioness L300 Go Results In Functional Gait Improvement In Patients With Parkinson’s Plus Syndromes.
Objective: To describe the efficacy of use of Bioness L300 Go FES System to result in functional improvement in gait related impairments in persons with…Whole-Exome Sequencing in a Movement Disorders Clinic
Objective: To evaluate the diagnostic utility of whole-exome sequencing (WES) in select patients with a movement disorder. Background: Many patients with suspected genetic movement disorders…The effect of Tuina in Traditional Chinese Medicine in treatment of Parkinson’s disease (Non-motor symptoms): a pilot clinical study
Objective: To evaluate the efficacy and safety of Tuina treatment in treating non-motor symptoms (NMS) of Parkinson’s disease (PD) and provide preliminary data for conducting…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…A retrospective review of clinical features of Progressive Supranuclear Palsy (PSP) in a movement disorders clinic
Objective: Understanding the common clinical features of PSP. Background: PSP is a relatively rare progressive neurodegenerative disease, which can often be difficult to distinguish from…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 405
- Next Page »